Apogee Therapeutics (APGE) Accumulated Expenses (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Accumulated Expenses data on file, last reported at $28.6 million in Q1 2026.

• Quarterly Accumulated Expenses rose 7.68% year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (up 7.68% YoY) and the FY2025 annual result came in at $23.2 million, down 4.43% from the prior year.
• Accumulated Expenses advanced to $28.6 million in Q1 2026 per APGE's latest filing, from $23.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $29.6 million in Q3 2025 and bottomed at $515000.0 in Q4 2022.
• The 5-year median for Accumulated Expenses is $21.8 million (2025), against an average of $17.1 million.
• The widest annual swing landed in 2023, when Accumulated Expenses jumped 3261.94%; it then decreased 4.43% in 2025.
• Tracing APGE's Accumulated Expenses over 5 years: stood at $515000.0 in 2022, then jumped by 3261.94% to $17.3 million in 2023, then soared by 40.09% to $24.3 million in 2024, then decreased by 4.43% to $23.2 million in 2025, then gained by 23.28% to $28.6 million in 2026.
• Per Business Quant, the three latest APGE Accumulated Expenses figures stand at $28.6 million (Q1 2026), $23.2 million (Q4 2025), and $29.6 million (Q3 2025).

Peer Comparison